ITOVEBI (inavolisib) tablets

ITOVEBI is a prescription medicine used to treat breast cancer. FDA approved inavolisib (brand name ITOVEBI) is not (yet) registered or available in India but on request Indian patient can buy ITOVEBI at the lowest price.

ITOVEBI-inavolisib-Price-Delhi-India
ITOVEBI (inavolisib) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ITOVEBI (inavolisib) tablets

Tezacaftor/ivacaftor and ivacaftor combination is used to treat cystic fibrosis (CF) in patients 6 years of age and older. It is only used for patients who have two copies of F508del mutation, or who have at least one mutation in their CF transmembrane conductance regulator (CFTR) gene.

ITOVEBI is a prescription medicine used in combination with the medicines palbociclib and fulvestrant to treat adults who
have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has
an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, and has spread to nearby tissue or
lymph nodes (locally advanced), or to other parts of the body (metastatic), and has come back after hormone (endocrine)
therapy.

Inavolisib is indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

ITOVEBI (inavolisib) tablets, for oral use Initial U.S. Approval: 2024
—————-
Current Indication: Treat f adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
—————-
Marketed By: Genentech
—————-
Approval Date: : 2024
—————-
Active ingredient: inavolisib
—————-
Inactive ingredients: lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablet filmcoating contains iron oxide red, and iron oxide yellow (in the 9 mg tablet only), macrogol/polyethylene glycol, polyvinyl
alcohol (partially hydrolyzed), talc, and titanium dioxide.
—————-

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.